Brief: Clover Announces Positive Phase 1 Results For Scb-219M For Treatment Of Chemotherapy-Induced Thrombocytopenia
29/12/2023 11:01
Dec 29 (Reuters) - Clover Biopharmaceuticals Ltd
2197.HK :
* CLOVER ANNOUNCES POSITIVE PHASE 1 RESULTS FOR SCB-219M FOR
TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)
* ALL CIT PATIENTS MAINTAINED PLATELET COUNTS >75 X 10(9)/L
AT
1-WEEK FOLLOWING CHEMOTHERAPY PLUS A SINGLE DOSE OF SCB-219M
* PHASE 1 B TRIAL EVALUATING REPEATED DOSING OF SCB-219M IN
CIT
AND CTIT PATIENTS IS PLANNED TO INITIATE IN 2024
Source text for Eikon: ID:nPn8R2C1va
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune